| Effects of Alpha Lipoic Acid on Multiple Cytokines and Biomarkers and Recurrence of Atrial Fibrillation Within 1 Year of Catheter Ablation 2017 · ALA group · Adults aged 18–75 with symptomatic, drug-refractory paroxysmal atrial fibrillation who received catheter ablation | 600 mg | 1 year | 49 |
| Effects of antioxidants on glutathione levels and clinical recovery from the malnutrition syndrome kwashiorkor--a pilot study 2005 · alpha-lipoic acid group · Children with severe kwashiorkor | 100 mg | 20 days | — |
| Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial 2011 · ALA · Adults aged 18–64 with type 1 or type 2 diabetes and mild-to-moderate diabetic distal symmetric sensorimotor polyneuropathy | 600 mg | 4 years | 230 |
| γ-Linolenic Acid versus α-Lipoic Acid for Treating Painful Diabetic Neuropathy in Adults: A 12-Week, Double-Placebo, Randomized, Noninferiority Trial 2020 · ALA and placebo · Adults aged 20–75 with type 2 diabetes and painful diabetic peripheral neuropathy | 600 mg | 12 weeks | 50 |
| The beneficial effect of Alpha-lipoic acid supplementation as a potential adjunct treatment in episodic migraines 2022 · ALA group · Women aged 20–50 with episodic migraine without aura and at least two attacks per month | 300 mg | 90 days | 47 |
| Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial 2006 · ALA600 · Adults with diabetes and distal symmetric polyneuropathy; age and sex not specified | 600 mg | 5 weeks | 45 |
| The effect of alpha lipoic acid supplementation on sperm functions in idiopathic asthenozoospermic patients: a case-controlled study 2023 · treatment group A · primary infertile males with idiopathic asthenozoospermia | 600 mg | 90 days | 40 |
| Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients 2022 · ALA group · Adult women aged 18 to under 70 with stage II or III breast cancer receiving doxorubicin, cyclophosphamide, and paclitaxel chemotherapy | 600 mg | 26 weeks | 32 |
| Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study 2008 · group 2 (thioctic acid) · Adults aged 29–85 with acute backache and moderate sciatica associated with a herniated disc | 600 mg | 60 days | 31 |
| [Clinical effect of acupuncture combined with medication on diabetic peripheral neuropathy and its influence on serum lipid metabolism] 2024 · combined therapy group · Adults with diabetic peripheral neuropathy; age and sex not reported | 600 mg | 4 weeks | 31 |
| [Clinical effect of acupuncture combined with medication on diabetic peripheral neuropathy and its influence on serum lipid metabolism] 2024 · medication group · Adults with diabetic peripheral neuropathy; age and sex not reported | 600 mg | 4 weeks | 29 |
| Effect of the administration of alpha-lipoic acid on contrast sensitivity in patients with type 1 and type 2 diabetes 2014 · T2DM patients receiving ALA · Adults with type 2 diabetes mellitus; mean age 59 ± 10 years | 300 mg | 90 days | 28 |
| Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy 1999 · TA 600 · Type 1 and Type 2 diabetic patients with symptomatic polyneuropathy | 600 mg | 2 years | 27 |
| Alpha lipoic acid efficacy in burning mouth syndrome. A controlled clinical trial 2015 · group B (ALA) · Adults over 18 years with clinically diagnosed burning mouth syndrome and continuous oral burning pain for more than 4 months | 600 mg | 60 days | 25 |
| Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial 2011 · Group C · Patients with burning mouth syndrome | 600 mg | 60 days | 20 |
| Gastrointestinal Tolerability and Absorption of R- Versus R,S-Lipoic Acid in Progressive Multiple Sclerosis: A Randomized Crossover Trial 2020 · R-lipoic acid · Adults with progressive multiple sclerosis; mean age 59.6 years; 12 women overall | 600 mg | 10 days | 20 |
| The effects of alpha lipoic acid on muscle strength recovery after a single and a short-term chronic supplementation - a study in healthy well-trained individuals after intensive resistance and endurance training 2020 · ALA supplementation · Healthy, well-trained male sports students; mean age 23.5 years, with strength- and endurance-training experience | 300 mg | 6 days | 17 |
| Treatment with α-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading 2015 · ALA treatment · Adults with type 2 diabetes and symptomatic diabetic sensorimotor polyneuropathy who responded to initial treatment; age and sex not specified | 600 mg | 16 weeks | 16 |
| Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study 2005 · lipoic acid · People with metabolic syndrome; age and sex not specified | 300 mg | 4 weeks | 15 |
| Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study 2005 · irbesartan plus lipoic acid · People with metabolic syndrome; age and sex not specified | 300 mg | 4 weeks | 15 |
| Alpha-lipoic acid improves subclinical left ventricular dysfunction in asymptomatic patients with type 1 diabetes 2013 · Insulin plus alpha-lipoic acid · Children and adolescents aged 10–14 with asymptomatic type 1 diabetes; sex not specified | 600 mg | 120 days | 15 |
| Effect of the administration of alpha-lipoic acid on contrast sensitivity in patients with type 1 and type 2 diabetes 2014 · Healthy controls receiving ALA · Healthy adults; mean age 33 ± 8 years | 300 mg | 90 days | 14 |
| Effect of Alpha-Lipoic Acid on Clinical and Neurophysiologic Recovery of Carpal Tunnel Syndrome: A Double-Blind, Randomized Clinical Trial 2018 · ALA treatment group · Adults with idiopathic carpal tunnel syndrome who underwent surgical decompression | 600 mg | 90 days | 10 |
| Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial 2022 · Alpha lipoic acid group · Adults aged 18–65 of either sex with treatment-resistant schizophrenia | 300 mg | 8 weeks | 10 |
| Effect of the administration of alpha-lipoic acid on contrast sensitivity in patients with type 1 and type 2 diabetes 2014 · T1DM patients receiving ALA · Adults with type 1 diabetes mellitus; mean age 43 ± 12 years | 300 mg | 90 days | 5 |
| Effects of alpha-lipoic acid supplementation in peripheral arterial disease: a pilot study 2007 · LA · Adults with peripheral arterial disease; mean age 73.2 years; 15 men and 13 women across both study arms | 600 mg | 90 days | — |
| Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss 2015 · α-lipoic acid · Healthy overweight or obese women following an energy-restricted diet | 300 mg | 10 weeks | — |
| Alpha Lipoic Acid (ALA) effects on subchorionic hematoma: preliminary clinical results 2015 · case study: ALA and Progesterone group · Pregnant women in the first trimester with threatened miscarriage and ultrasound evidence of subchorionic hematoma | 600 mg | — | — |
| Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial 2016 · α-lipoic acid · Adults with diabetes and mild-to-moderate diabetic polyneuropathy | 600 mg | 4 years | — |
| Effects of probiotic and alpha-lipoic acid supplements, separately or in combination on the anthropometric indicators and maintenance of weight in overweight individuals 2021 · ALA group · Overweight individuals | 600 mg | 24 weeks | — |
| Safety and efficacy of alpha-lipoic acid oral supplementation in the reduction of pain with unknown etiology: A monocentric, randomized, double-blind, placebo-controlled clinical trial 2021 · 400 mg/day ALA · Normoglycemic adults with idiopathic neuropathic pain, arthralgia, or myalgia; age and sex not specified | 400 mg | 60 days | — |
| Short-Term Dietary Caffeine Intake for Alleviating Symptoms of Burning Mouth Syndrome: A Randomised Controlled Comparison With Alpha-Lipoic Acid 2025 · ALA group · BMS patients; age and sex not specified | 600 mg | 2 weeks | — |
| Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled Study 2020 · oral ALA · Patients with diabetic peripheral neuropathy; age range and sex not reported | 1.2 g | 26 weeks | 100 |
| α-Lipoic acid and superoxide dismutase in the management of chronic neck pain: a prospective randomized study 2014 · ALA/SOD plus physiotherapy · Adults over 18 with chronic neck pain lasting at least 3 months | 600 mg | 60 days | 51 |
| Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial 2006 · ALA1200 · Adults with diabetes and distal symmetric polyneuropathy; age and sex not specified | 1.2 g | 5 weeks | 47 |
| Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie 1997 · ALA · Patients with NIDDM and reduced heart rate variability, with cardiac autonomic neuropathy | 800 mg | 122 days | 39 |
| Alpha-Lipoic Acid and Antioxidant Diet Help to Improve Endothelial Dysfunction in Adolescents with Type 1 Diabetes: A Pilot Trial 2015 · 10,000 ORAC antioxidant diet plus alpha-lipoic acid (group 1) · Adolescents aged 12–19 years with type 1 diabetes | 800 mg | 26 weeks | 25 |
| The synergic effects of alpha-lipoic acid supplementation and electrical isotonic contraction on anthropometric measurements and the serum levels of VEGF, NO, sirtuin-1, and PGC1-α in obese people undergoing a weight loss diet 2022 · α-LA · obese adults undergoing a weight-loss diet | 1.2 g | 8 weeks | 25 |
| The synergic effects of alpha-lipoic acid supplementation and electrical isotonic contraction on anthropometric measurements and the serum levels of VEGF, NO, sirtuin-1, and PGC1-α in obese people undergoing a weight loss diet 2022 · α-LA + Faradic · obese adults undergoing a weight-loss diet | 1.2 g | 8 weeks | 25 |
| Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics 2024 · ALA group · Adults aged 18–60 with persistent post-COVID olfactory dysfunction, including smell loss and parosmia | 800 mg | 180 days | 21 |
| Gastrointestinal Tolerability and Absorption of R- Versus R,S-Lipoic Acid in Progressive Multiple Sclerosis: A Randomized Crossover Trial 2020 · R,S-lipoic acid mixture · Adults with progressive multiple sclerosis; mean age 59.6 years; 12 women overall | 1.2 g | 10 days | 20 |
| Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy 1999 · TA 1200 · Type 1 and Type 2 diabetic patients with symptomatic polyneuropathy | 1.2 g | 2 years | 18 |
| Acute mountain sickness; prophylactic benefits of antioxidant vitamin supplementation at high altitude 2001 · antioxidant group · Adults aged 35 ± 10 years ascending to high altitude; no diagnosed condition reported | 600 mg | 31 days | 9 |
| Effects of alpha-lipoic Acid on body weight in obese subjects 2011 · alpha-lipoic acid 1200 mg/d · Obese adults with BMI ≥30 kg/m², or BMI 27–30 kg/m² plus hypertension, diabetes mellitus, or hypercholesterolemia | 1.2 g | 20 weeks | — |
| Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis 2018 · lipoic acid (LA) · Adults aged 40–70 with secondary progressive multiple sclerosis (SPMS), able to walk at least 25 feet without an aid | 1.2 g | 2 years | — |
| Safety and efficacy of alpha-lipoic acid oral supplementation in the reduction of pain with unknown etiology: A monocentric, randomized, double-blind, placebo-controlled clinical trial 2021 · 800 mg/day ALA · Normoglycemic adults with idiopathic neuropathic pain, arthralgia, or myalgia; age and sex not specified | 800 mg | 60 days | — |
| The role of oral alpha-lipoic acid as an adjuvant antioxidant therapy in diabetic nephropathy among children and adolescents with type 1 diabetes: a randomized controlled trial 2026 · interventional arm · children and adolescents with type 1 diabetes and diabetic nephropathy | 300 mg | 90 days | 25 |
| [Efficacy and safety of high-dose α-lipoic acid in the treatment of diabetic polyneuropathy] 2010 · α-lipoic acid · People with diabetes and symptomatic polyneuropathy; age and sex not specified | 1.8 g | 12 weeks | 117 |
| Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial 2006 · ALA1800 · Adults with diabetes and distal symmetric polyneuropathy; age and sex not specified | 1.8 g | 5 weeks | 46 |
| Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy 1999 · TA group · Patients with type 2 diabetes mellitus and symptomatic polyneuropathy | 1.8 g | 3 weeks | 12 |
| Effects of alpha-lipoic Acid on body weight in obese subjects 2011 · alpha-lipoic acid 1800 mg/d · Obese adults with BMI ≥30 kg/m², or BMI 27–30 kg/m² plus hypertension, diabetes mellitus, or hypercholesterolemia | 1.8 g | 20 weeks | — |
| Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease 2010 · alpha-LA therapy · Patients with Parkinson's disease, low bone mineral density, and taking levodopa; age and sex not reported | 1.2 g | 1 year | — |
| Randomized controlled trial of bromelain and alpha-lipoic acid in breast conservative surgery 2025 · Group A: CBB + neurotrophic agents · Women aged over 18 with breast cancer undergoing breast-conserving surgery | 400 mg | 30 days | 39 |
| Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy 1999 · A-A · Adults with type 2 diabetes and symptomatic polyneuropathy | 600 mg | 29 weeks | 167 |
| Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study) 2004 · Alpha-lipoic acid group · Adults with type 1 diabetes and autonomic neuropathy; mean age 38.1 years | 600 mg | 60 days | 46 |
| Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics 2024 · Combined group · Adults aged 18–60 with persistent post-COVID olfactory dysfunction, including smell loss and parosmia | 600 mg | 180 days | 28 |
| Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus 2013 · alpha-lipoic acid · men with erectile dysfunction and type 2 diabetes mellitus | 600 mg | 12 weeks | — |
| Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss 2015 · EPA+α-lipoic acid · Healthy overweight or obese women following an energy-restricted diet | 300 mg | 10 weeks | — |
| Effects of probiotic and alpha-lipoic acid supplements, separately or in combination on the anthropometric indicators and maintenance of weight in overweight individuals 2021 · ALA and probiotic group · Overweight individuals | 600 mg | 24 weeks | — |
| The Impact of Decaffeinated Green Tea Extract on Fat Oxidation, Body Composition and Cardio-Metabolic Health in Overweight, Recreationally Active Individuals 2021 · dGTE+ · Adults over 18 who were recreationally active and overweight (BMI 25.0–29.9 kg/m² and/or body fat in the overweight category); healthy, without the listed cardio-metabolic or blood/liver disorders | 150 mg | 8 weeks | — |
| Effects of alpha lipoic acid on iron overload, lipid profile and oxidative stress indices in β-thalassemia major patients: A cross-over randomised controlled clinical trial 2021 · ALA · Patients with β-thalassemia major | 600 mg | 8 weeks | 26 |
| Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers 2014 · Thioctacid HR (reference), part 2 · Healthy volunteers | 600 mg | 1 day | 24 |
| Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers 2014 · PDT-2, part 2 · Healthy volunteers | 600 mg | 1 day | 24 |
| Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers 2014 · Thioctacid HR (reference), part 1 · Healthy volunteers | 600 mg | 1 day | 8 |
| Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers 2014 · PDT-1, part 1 · Healthy volunteers | 600 mg | 1 day | 8 |
| Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers 2014 · PDT-2, part 1 · Healthy volunteers | 600 mg | 1 day | 8 |
| Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid 2002 · controlled-release LA (CRLA), pharmacokinetic study · 12 normal human subjects | 600 mg | 1 day | — |
| Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid 2002 · quick-release LA (QRLA), pharmacokinetic study · 12 normal human subjects | 600 mg | 1 day | — |
| Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers 1998 · oral 200 mg · 12 healthy volunteers; age and sex not stated | 200 mg | 1 day | — |
| Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers 1998 · oral 600 mg · 12 healthy volunteers; age and sex not stated | 600 mg | 1 day | — |
| Acute reversal of endothelial dysfunction in the elderly after antioxidant consumption 2012 · Antioxidant cocktail · Healthy young adults (mean age 25 ± 1 years) and older adults (mean age 71 ± 1 years), free of overt cardiovascular disease | 600 mg | 1 day | 87 |
| Vascular dysfunction and chronic obstructive pulmonary disease: the role of redox balance 2014 · Antioxidant cocktail (AOC) · Adults: 30 patients with COPD and 30 age- and sex-matched controls | 600 mg | 1 day | 60 |
| Combined Rehabilitation with Alpha Lipoic Acid, Acetyl-L-Carnitine, Resveratrol, and Cholecalciferolin Discogenic Sciatica in Young People: A Randomized Clinical Trial 2023 · Combo group (CG) · Adults aged 18–45 with acute sciatica due to lumbar disc herniation and low-back pain NRS 5–7 | 600 mg | 30 days | 44 |
| Efficacy and Safety of the Combination of Superoxide Dismutase, Alpha Lipoic Acid, Vitamin B12, and Carnitine for 12 Months in Patients with Diabetic Neuropathy 2020 · Group A · Adults with type 2 diabetes, established peripheral and autonomic neuropathy, and at least four years of metformin treatment | 570 mg | 1 year | 43 |
| Combined Rehabilitation with Alpha Lipoic Acid, Acetyl-L-Carnitine, Resveratrol, and Cholecalciferolin Discogenic Sciatica in Young People: A Randomized Clinical Trial 2023 · Supplement group (SG) · Adults aged 18–45 with acute sciatica due to lumbar disc herniation and low-back pain NRS 5–7 | 600 mg | 30 days | 41 |
| Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy 2024 · 10-element combination tablet · Overweight or obese adults with type 2 diabetes and mild-to-moderate painful diabetic neuropathy; mean age 63 years | 600 mg | 26 weeks | 36 |
| Effects of 12 Weeks of Essential Amino Acids (EAA)-Based Multi-Ingredient Nutritional Supplementation on Muscle Mass, Muscle Strength, Muscle Power and Fatigue in Healthy Elderly Subjects: A Randomized Controlled Double-Blind Study 2019 · multi-ingredient nutritional supplement (SUPP) · Healthy men and women aged 65–80 years, not selected for a diagnosed disease; the group was described as non-sarcopenic and well-nourished | 600 mg | 12 weeks | 19 |
| Effects of Macuprev(®) Supplementation in Age-Related Macular Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6 Months of Follow-Up 2019 · AMD-M group · Adults with intermediate age-related macular degeneration; 9 male and 21 female enrolled overall, mean age 69.32 years | 140 mg | 26 weeks | 15 |
| The impact of lipoic acid on endothelial function and proteinuria in quinapril-treated diabetic patients with stage I hypertension: results from the QUALITY study 2012 · QUI + ALA · Adults with diabetes and Stage I hypertension | 600 mg | 8 weeks | 40 |
| The effect of lipoic acid and vitamin E therapies in individuals with the metabolic syndrome 2013 · ALA · People with metabolic syndrome | 600 mg | 1 year | 34 |
| Effect of alpha lipoic acid on the blood cell count and iron kinetics in hypertensive patients 2014 · treatment group · Hypertensive adults, with or without anemia; age and sex not specified | 600 mg | 12 weeks | 32 |
| Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis 2012 · supplemented group · Adults aged 22–79 with end-stage renal disease undergoing maintenance hemodialysis | 600 mg | 8 weeks | 31 |
| Alpha lipoic acid supplementation improved antioxidant enzyme activities in hemodialysis patients 2019 · ALA group · Adults aged 22–79 with hemodialysis; 43 males and 20 females across the study | 600 mg | 8 weeks | 31 |
| Alpha-lipoic acid supplementation effects on serum values of some oxidative stress biomarkers in women with gestational diabetes 2021 · drug group · Women with gestational diabetes at 24–28 weeks of pregnancy | 300 mg | 8 weeks | 30 |
| Alpha-lipoic acid improved anemia, erythropoietin resistance, maintained glycemic control, and reduced cardiovascular risk in diabetic patients on hemodialysis: a multi-center prospective randomized controlled study 2022 · alpha-lipoic acid group · Adults with diabetes receiving hemodialysis | 600 mg | 26 weeks | 30 |
| Impact of Alpha Lipoic Acid as an Adjuvant Therapy on Inflammation and Fibrosis in Type 2 Diabetic Patients with Ischemic Cardiomyopathy: A Randomized Controlled Trial 2026 · ALA group · Adults aged 45–75 with type 2 diabetes and ischemic cardiomyopathy | 600 mg | 90 days | 30 |
| The effect of alpha-lipoic acid (ALA) supplementation on cardiovascular risk factors in men with chronic spinal cord injury: a clinical trial 2015 · ALA group · Men with chronic spinal cord injury; age not reported | 600 mg | 12 weeks | 28 |
| The effects of lipoic acid and α-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial 2011 · 600 mg LA · Patients with type 2 diabetes mellitus; age and sex not reported | 600 mg | 120 days | 26 |
| Effect of α-lipoic acid on platelet reactivity in type 1 diabetic patients 2012 · ALA group · People with type 1 diabetes without evidence of cardiovascular disease; age and sex range not stated | 600 mg | 5 weeks | 26 |
| A randomized, double-blind, placebo controlled study to evaluate the effect of alpha-lipoic acid on inhibition of ADP-and collagen-induced platelet aggregation ex vivo in diabetic neuropathy patients on gabapentin or pregabalin 2024 · ALA · Adults aged 30–65 of either sex with symptomatic diabetic peripheral neuropathy and type 2 diabetes, taking stable gabapentin or pregabalin | 600 mg | 12 weeks | 26 |
| Lack of interaction between thioctic acid, glibenclamide and acarbose 1999 · A (600 mg TA) · 24 healthy adult volunteers: 14 men and 10 women | 600 mg | 1 day | 24 |
| Lack of interaction between thioctic acid, glibenclamide and acarbose 1999 · C (600 mg TA + 3.5 mg glibenclamide) · 24 healthy adult volunteers: 14 men and 10 women | 600 mg | 1 day | 24 |
| Lack of interaction between thioctic acid, glibenclamide and acarbose 1999 · D (600 mg TA + 50 mg acarbose) · 24 healthy adult volunteers: 14 men and 10 women | 600 mg | 1 day | 24 |
| Gastric emptying in patients with insulin dependent diabetes mellitus and bioavailability of thioctic acid-enantiomers 1998 · oral single-dose administration · Adults with insulin-dependent diabetes mellitus; gastric emptying was normal in 11 and delayed in 11 | 200 mg | 1 day | 22 |
| [Diabetes mellitus--a free radical-associated disease. Results of adjuvant antioxidant supplementation] 1993 · alpha lipoic acid group · Patients with diabetes mellitus and long-term diabetic late syndrome; age and sex not reported | 600 mg | 90 days | 20 |
| Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial 1999 · 600 mg once daily · Patients with type-2 diabetes mellitus; age and sex not reported | 600 mg | 4 weeks | 19 |
| Untargeted metabolomic on urine samples after α-lipoic acid and/or eicosapentaenoic acid supplementation in healthy overweight/obese women 2018 · α-LA group · Healthy sedentary overweight/obese women, mean age 37.3 years; following a hypocaloric diet | 300 mg | 10 weeks | 16 |
| Metabolic effects of α-lipoic acid supplementation in pre-diabetics: a randomized, placebo-controlled pilot study 2019 · α-lipoic acid treatment · Pre-diabetic, overweight/obese adults with dyslipidemia | 600 mg | 30 days | 12 |
| Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study 2007 · treatment group · Diabetic patients with end-stage renal disease undergoing hemodialysis | 600 mg | 12 weeks | — |
| The comparison of antioxidant and hematological properties of N-acetylcysteine and alpha-lipoic acid in physically active males 2009 · Alpha-lipoic acid (ALA) · Healthy, physically active men | 600 mg | 8 days | — |
| Assessment of the antioxidant effectiveness of alpha-lipoic acid in healthy men exposed to muscle-damaging exercise 2009 · T(ALA) group · trained men; age and health condition not stated | 600 mg | 8 days | — |
| Impact of therapy with alpha-lipoic acid (ALA) on the oxidative stress in the controlled NIDDM: a possible preventive way against the organ dysfunction? 2009 · ALA group · Patients with controlled non-insulin dependent diabetes mellitus (NIDDM) | 400 mg | 4 weeks | — |
| Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients 2011 · ALA group · people with type 2 diabetes; age and sex not reported | 300 mg | 8 weeks | — |
| Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha-lipoic acid: a randomized double-blinded placebo-controlled study 2012 · 300 mg/day ALA · Adults with type 2 diabetes mellitus | 300 mg | 26 weeks | — |
| Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha-lipoic acid: a randomized double-blinded placebo-controlled study 2012 · 600 mg/day ALA · Adults with type 2 diabetes mellitus | 600 mg | 26 weeks | — |
| Effects of α-lipoic acid therapy on sympathetic heart innervation in patients with previous experience of transient takotsubo cardiomyopathy 2016 · α-lipoic acid (ALA) treatment · Patients with previous takotsubo cardiomyopathy | 600 mg | 1 year | — |
| Lack of a Clinically Significant Pharmacokinetic Interaction Between Pregabalin and Thioctic Acid in Healthy Volunteers 2018 · thioctic acid alone · healthy male volunteers; age not reported | 600 mg | — | — |
| Lack of a Clinically Significant Pharmacokinetic Interaction Between Pregabalin and Thioctic Acid in Healthy Volunteers 2018 · pregabalin and thioctic acid combination · healthy male volunteers; age not reported | 600 mg | — | — |
| Effect of lipoic acid supplementation on gene expression and activity of glutathione S-transferase enzyme in infertile men 2021 · lipoic acid group · Men with idiopathic asthenozoospermia | 600 mg | 12 weeks | — |
| A Randomized Controlled Trial of Long-Term (R)-α-Lipoic Acid Supplementation Promotes Weight Loss in Overweight or Obese Adults without Altering Baseline Elevated Plasma Triglyceride Concentrations 2020 · (R)-α-lipoic acid (R-LA) · Overweight or obese adults aged 21–60 years with BMI ≥25 and elevated plasma triglycerides ≥100 mg/dL | 600 mg | 24 weeks | — |
| The efficacy of alpha-lipoic acid in improving oxidative, inflammatory, and mood status in women with episodic migraine in a randomised, double-blind, placebo-controlled clinical trial 2021 · ALA group · Women with episodic migraine | 600 mg | 90 days | — |
| Restoration of blood total glutathione status and lymphocyte function following alpha-lipoic acid supplementation in patients with HIV infection 2008 · ALA · HIV-infected men and women aged 44–47 years with viral load >10,000 copies/cm(3) despite HAART | 900 mg | 26 weeks | — |
| The Beneficial Effects of α-Lipoic Acid in Critically Ill Patients: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial 2018 · ALA group · Critically ill patients expected to stay at least seven days in the ICU and requiring enteral feeding | 900 mg | 10 days | 40 |
| Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy 1997 · ALA · Adults with NIDDM and cardiac autonomic neuropathy diagnosed by reduced heart rate variability | 800 mg | 120 days | 39 |
| The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial 2020 · intervention group (ALA group) · Adults aged 40–60 with type 2 diabetes for at least two years, HbA1c <7%, and BMI 18.5–29.9 | 1.2 g | 8 weeks | 35 |
| Effect of Alpha-Lipoic Acid Supplementation on Endothelial Function and Cardiovascular Risk Factors in Overweight/Obese Youths: A Double-Blind, Placebo-Controlled Randomized Trial 2019 · ALA · Children and adolescents aged 8–16 years with overweight or obesity (BMI above the 85th percentile) | 800 mg | 12 weeks | 34 |
| Elevation of the adiponectin/leptin ratio in women with gestational diabetes mellitus after supplementation with alpha-lipoic acid 2019 · drug group · Pregnant women diagnosed with gestational diabetes mellitus at 24–28 weeks of pregnancy | 100 mg | 8 weeks | 30 |
| Reduction in maternal serum values of glucose and gamma-glutamyltransferase after supplementation with alpha-lipoic acid in women with gestational diabetes mellitus 2019 · drug group · Women aged 24–28 weeks of gestation with gestational diabetes mellitus | 100 mg | 8 weeks | 30 |
| Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid 2002 · 900 mg CRLA daily, first treatment period · Patients with type 2 diabetes | 900 mg | 6 weeks | 21 |
| Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid 2002 · 1,200 mg CRLA daily, second treatment period · Patients with type 2 diabetes | 1.2 g | 6 weeks | 21 |
| Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial 1999 · 1200 mg twice daily · Patients with type-2 diabetes mellitus; age and sex not reported | 1.2 g | 4 weeks | 18 |
| Effects of α-lipoic acid on mtDNA damage after isolated muscle contractions 2013 · α-lipoic acid supplement group · Apparently healthy men, mean age 28 years | 1 g | 2 weeks | 6 |
| Lipoic acid in multiple sclerosis: a pilot study 2005 · LA 600 mg twice a day · Patients with multiple sclerosis; age and sex not reported | 1.2 g | 2 weeks | — |
| Lipoic acid in multiple sclerosis: a pilot study 2005 · LA 1200 mg once a day · Patients with multiple sclerosis; age and sex not reported | 1.2 g | 2 weeks | — |
| Effect of cysteine derivatives administration in healthy men exposed to intense resistance exercise by evaluation of pro-antioxidant ratio 2007 · Alpha-lipoic acid (LIP) · Healthy men exposed to intense resistance exercise | 1.2 g | 3 days | — |
| Effects of sulphur-containing compounds on plasma redox status in muscle-damaging exercise 2009 · Alpha-lipoic acid (ALA) · Healthy, trained men | 1.2 g | 3 days | — |
| Oxidative stress in preretinopathic diabetes subjects and antioxidants 2012 · oral antioxidant treatment group · people with preretinopathic diabetes and good metabolic control | 400 mg | 30 days | — |
| Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha-lipoic acid: a randomized double-blinded placebo-controlled study 2012 · 900 mg/day ALA · Adults with type 2 diabetes mellitus | 900 mg | 26 weeks | — |
| Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha-lipoic acid: a randomized double-blinded placebo-controlled study 2012 · 1200 mg/day ALA · Adults with type 2 diabetes mellitus | 1.2 g | 26 weeks | — |
| Physical activity and alpha-lipoic acid modulate inflammatory response through changes in thiol redox status 2013 · αLA · Physically active males | 1.2 g | 10 days | — |
| Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: a randomized controlled clinical trial 2014 · lipoic acid · Adults aged 18–50 years with relapsing-remitting multiple sclerosis and EDSS ≤5.5 | 1.2 g | 12 weeks | — |
| Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: a double-blind, placebo-controlled, randomized clinical trial 2014 · LA consumption · Adults aged 18–50 with relapsing-remitting multiple sclerosis | 1.2 g | 12 weeks | — |
| α-Tocopherol supplementation reduces biomarkers of oxidative stress in children with Down syndrome: a randomized controlled trial 2014 · ALA · Children aged 7–15 years, both sexes, with Down syndrome | 100 mg | 120 days | — |
| Oral α-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: effects on adipokines and liver histology features 2019 · α-LA group · Patients with non-alcoholic fatty liver disease; described as obese, ages and sex not reported | 1.2 g | 12 weeks | — |
| Complementary therapy in diabetic patients with chronic complications: a pilot study 2010 · QALAPL group · Patients with diabetes; age and sex not reported | 100 mg | 90 days | 20 |
| The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial 2019 · ALA · Obese patients with non-alcoholic fatty liver disease; age and sex not specified | 1.2 g | 12 weeks | 23 |
| Complementary therapy in diabetic patients with chronic complications: a pilot study 2010 · QALA group · Patients with diabetes; age and sex not reported | 100 mg | 90 days | 20 |
| Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial 1999 · 1800 mg three times daily · Patients with type-2 diabetes mellitus; age and sex not reported | 1.8 g | 4 weeks | 18 |
| Lipoic acid in multiple sclerosis: a pilot study 2005 · LA 1200 mg twice a day · Patients with multiple sclerosis; age and sex not reported | 2.4 g | 2 weeks | — |
| Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy 2013 · supplement group · Patients with diabetic nephropathy; age and sex not reported | 800 mg | 12 weeks | — |
| The effects of lipoic acid and α-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial 2011 · 800 mg α-tocopherol + 600 mg LA · Patients with type 2 diabetes mellitus; age and sex not reported | 600 mg | 120 days | 25 |
| Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress 1999 · LA alone for 2 months, followed by LA and AT combination for 2 months · Healthy adults; age and sex not specified | 600 mg | 120 days | 16 |
| Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress 1999 · AT alone for 2 months, followed by LA and AT combination for 2 months · Healthy adults; age and sex not specified | 600 mg | 120 days | 15 |
| Untargeted metabolomic on urine samples after α-lipoic acid and/or eicosapentaenoic acid supplementation in healthy overweight/obese women 2018 · EPA + α-LA · Healthy sedentary overweight/obese women, mean age 37.3 years; following a hypocaloric diet | 300 mg | 10 weeks | 15 |
| A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease 2014 · ω-3 + LA · Adults aged 55 years or older with probable Alzheimer’s disease | 600 mg | 1 year | 13 |
| Effect of alpha-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration 2003 · Creatine monohydrate + sucrose + alpha-lipoic acid · Male subjects aged 18–32 years | 1 g | 5 days | — |
| Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures 2012 · E/C/ALA · Adults aged 50–85 with probable Alzheimer disease and MMSE scores of 16 or more | 900 mg | 16 weeks | — |
| Effects of α-Lipoic Acid, Carnosine, and Thiamine Supplementation in Obese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind Study 2018 · supplement group · Obese adults with type 2 diabetes mellitus | 7 mg/kg | 8 weeks | — |
| A Clinical Trial about a Food Supplement Containing α-Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients 2016 · food supplement containing α-lipoic acid · Caucasian adults aged 18–75 years, both sexes, with overweight and type 2 diabetes and HbA1c >7.0% | 600 mg | 90 days | 54 |
| Nutraceutical Effects on Glucose and Lipid Metabolism in Patients with Impaired Fasting Glucose: A Pilot, Double-Blind, Placebo-Controlled, Randomized Clinical Trial on a Combined Product 2017 · Active nutraceutical · Adults with impaired fasting glucose, ages 54.6 ± 11.3 years on average; men and women | 220 mg | 8 weeks | 20 |
| Plasma C-reactive protein concentrations in active and passive smokers: influence of antioxidant supplementation 2004 · antioxidant mixture · Healthy adult men and women who were active or passive smokers | 95 mg | 60 days | — |
| An Exploratory Investigation of Endotoxin Levels in Novice Long Distance Triathletes, and the Effects of a Multi-Strain Probiotic/Prebiotic, Antioxidant Intervention 2016 · LAB4 ANTI · Recreationally active adults aged about 35 years, 25 men and 5 women in the overall study cohort, training for their first long-distance triathlon | 400 mg | 90 days | — |
| Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial 2011 · Group A · Patients with burning mouth syndrome | 600 mg | 60 days | 20 |